HNO

, Volume 58, Issue 8, pp 778–790 | Cite as

Prophylaktische und therapeutische Vakzinen gegen humane Papillomviren

  • A.E. Albers
  • T.K. Hoffmann
  • J.P. Klussmann
  • A.M. Kaufmann
Übersichten

Zusammenfassung

Neben der rezidivierenden Papillomatose gilt inzwischen auch der kausale Zusammenhang zwischen Infektionen mit humanen Papillomviren (HPV) und einer Subgruppe von Plattenepithelkarzinom des Kopf-Hals-Bereichs als gesichert. Durch Einführung prophylaktischer HPV-Vakzinen für Mädchen gegen die häufigsten Hochrisiko-Typen darf künftig auch von einer Änderung der Prävalenz insbesondere oropharyngealer Karzinome bei Patientinnen gerechnet werden. Die Impfung gegen die wichtigsten Niedrigrisiko-HPV-Typen zeigte eine hohe Effektivität gegen Genitalwarzen und sollte auch eine Effektivität gegen Papillomatosen aufweisen. Neue Möglichkeiten der prophylaktischen HPV-Impfung sowie Entwicklungen und Hintergrund therapeutischer Vakzinen werden anhand der aktuellen Studienlage diskutiert.

Schlüsselwörter

Plattenepithelkarzinom Rezidivierende respiratorische Papillomatose Humanes Papillomvirus Präventive Impfung Therapeutische Impfung 

Prophylactic and therapeutic vaccines against human papilloma virus

Abstract

Infection with human papilloma virus (HPV) has been identified as the cause of recurrent papillomatosis and of a subgroup of squamous cell carcinomas of the head and neck. A change in prevalence of these lesions, especially for oropharyngeal carcinoma, can be expected as a consequence of the introduction of prophylactic HPV vaccines for young women, targeting the most frequent high- and low-risk HPV subtypes. Vaccination for the major low-risk HPV types has proven to be highly effective against genital warts and activity against papillomatosis can be expected. The possibilities of prophylactic HPV vaccination as well as new developments and the rationale for therapeutic vaccines are discussed on the basis of the current literature.

Keywords

Squamous cell carcinoma Recurrent respiratory papillomatosis Human papilloma virus Prophylactic vaccination Therapeutic vaccination 

Notes

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehung(en) hin: PD Dr. Andreas Kaufmann erhielt in den letzten 5 Jahren Vortrags- und Beraterhonorare von GSK und Sanofi-Pasteur/MSD. Prof. Dr. Jens Peter Klussmann erhielt in den letzten 5 Jahren Vortragshonorare von Sanofi-Pasteur/MSD. Es besteht kein Interessenkonflikt der anderen Autoren.

Literatur

  1. 1.
    Aaltonen LM, Auvinen E, Dillner J et al (2001) Poor antibody response against human papillomavirus in adult-onset laryngeal papillomatosis. J Med Microbiol 50:468–471PubMedGoogle Scholar
  2. 2.
    Albers A, Abe K, Hunt J et al (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65:11146–11155PubMedCrossRefGoogle Scholar
  3. 3.
    Albers AE, Ferris RL, Kim GG et al (2005) Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 54:1072–1081PubMedCrossRefGoogle Scholar
  4. 4.
    Albers A, Kaufmann AM (2009) Therapeutic human papillomavirus vaccination. Public Health Genomics 12:331–342PubMedCrossRefGoogle Scholar
  5. 5.
    AWMF-Online (o J) Impfprävention HPV-assoziierter Neoplasien. http://www.uni-duesseldorf.de/AWMF/ll/082–002.htmGoogle Scholar
  6. 6.
    Barr E, Gause CK, Bautista OM et al (2008) Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of north American women. Am J Obstet Gynecol 198:261, e261–e211PubMedCrossRefGoogle Scholar
  7. 7.
    Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32(Suppl 1):S16–S24PubMedCrossRefGoogle Scholar
  8. 8.
    Bergmann C, Strauss L, Wang Y et al (2008) T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 14:3706–3715PubMedCrossRefGoogle Scholar
  9. 9.
    Bergmann C, Strauss L, Wieckowski E et al (2009) Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck 31:371–380PubMedCrossRefGoogle Scholar
  10. 10.
    Bergmann C, Strauss L, Zeidler R et al (2007) Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma. Cancer Res 67:8865–8873PubMedCrossRefGoogle Scholar
  11. 11.
    Brinkman JA, Hughes SH, Stone P et al (2007) Therapeutic vaccination for HPV induced cervical cancers. Dis Markers 23:337–352PubMedGoogle Scholar
  12. 12.
    Brown DR, Shew ML, Qadadri B et al (2005) A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191:182–192PubMedCrossRefGoogle Scholar
  13. 13.
    Carter JJ, Koutsky LA, Hughes JP et al (2000) Comparison of human papillomavirus types 16, 18 and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911–1919PubMedCrossRefGoogle Scholar
  14. 14.
    Castle PE, Solomon D, Schiffman M et al (2005) Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 97:1066–1071PubMedCrossRefGoogle Scholar
  15. 15.
    Clifford GM, Smith JS, Plummer M et al (2003) Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88:63–73PubMedCrossRefGoogle Scholar
  16. 16.
    Cogliano V, Baan R, Straif K et al (2005) Carcinogenicity of human papillomaviruses. Lancet Oncol 6:204PubMedCrossRefGoogle Scholar
  17. 17.
    Coleman N, Birley HD, Renton AM et al (1994) Immunological events in regressing genital warts. Am J Clin Pathol 102:768–774PubMedGoogle Scholar
  18. 18.
    Cruz IB, Snijders PJ, Steenbergen RD et al (1996) Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 32B:55–62PubMedCrossRefGoogle Scholar
  19. 19.
    De Jong A, Van Der Burg SH, Kwappenberg KM et al (2002) Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res 62:472–479Google Scholar
  20. 20.
    De Jong A, Van Poelgeest MI, Van Der Hulst JM et al (2004) Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449–5455CrossRefGoogle Scholar
  21. 21.
    Dedo HH, Yu KC (2001) CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope 111:1639–1644PubMedCrossRefGoogle Scholar
  22. 22.
    Derkay CS (1995) Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 121:1386–1391PubMedGoogle Scholar
  23. 23.
    Derkay CS, Smith RJ, McClay J et al (2005) HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol 114:730–737PubMedGoogle Scholar
  24. 24.
    Donne AJ, Hampson L, He XT et al (2009) Cidofovir induces an increase in levels of low-risk and high-risk HPV E6. Head Neck 31:893–901PubMedCrossRefGoogle Scholar
  25. 25.
    Fakhry C, D’Souza G, Sugar E et al (2006) Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and -negative women. J Clin Microbiol 44:4479–4485PubMedCrossRefGoogle Scholar
  26. 26.
    Fakhry C, Gillison ML (2006) Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 24:2606–2611PubMedCrossRefGoogle Scholar
  27. 27.
    Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269PubMedCrossRefGoogle Scholar
  28. 28.
    Ferenczy A, Coutlee F, Franco E et al (2003) Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. CMAJ 169:431–434PubMedGoogle Scholar
  29. 29.
    Forster G, Boltze C, Seidel J et al (2008) Juvenile laryngeal papillomatosis – immunisation with the polyvalent vaccine gardasil. Laryngorhinootologie 87:796–799PubMedCrossRefGoogle Scholar
  30. 30.
    Franco EL, Villa LL, Sobrinho JP et al (1999) Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 180:1415–1423PubMedCrossRefGoogle Scholar
  31. 31.
    Freed GL, Derkay CS (2006) Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Pediatr Otorhinolaryngol 70:1799–1803PubMedCrossRefGoogle Scholar
  32. 32.
    Garcia-Hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A et al (2006) Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13:592–597PubMedCrossRefGoogle Scholar
  33. 33.
    Gerein V, Rastorguev E, Gerein J et al (2005) Incidence, age at onset and potential reasons of malignant transformation in recurrent respiratory papillomatosis patients: 20 years experience. Otolaryngol Head Neck Surg 132:392–394PubMedCrossRefGoogle Scholar
  34. 34.
    Ghim S, Newsome J, Bell J et al (2000) Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 68:147–151PubMedCrossRefGoogle Scholar
  35. 35.
    Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709–720PubMedCrossRefGoogle Scholar
  36. 36.
    Gillison ML, Koch WM, Shah KV (1999) Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol 11:191–199PubMedCrossRefGoogle Scholar
  37. 37.
    Gillison ML, Lowy DR (2004) A causal role for human papillomavirus in head and neck cancer. Lancet 363:1488–1489PubMedCrossRefGoogle Scholar
  38. 38.
    Gillison ML, Shah KV (2001) Human papillomavirus-associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers. Curr Opin Oncol 13:183–188PubMedCrossRefGoogle Scholar
  39. 39.
    Giuliano AR, Lazcano-Ponce E, Villa L et al (2007) Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis 196:1153–1162PubMedCrossRefGoogle Scholar
  40. 40.
    Go C, Schwartz MR, Donovan DT (2003) Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann Otol Rhinol Laryngol 112:298–302PubMedGoogle Scholar
  41. 41.
    Hafkamp HC, Manni JJ, Speel EJ (2004) Role of human papillomavirus in the development of head and neck squamous cell carcinomas. Acta Otolaryngol 124:520–526PubMedCrossRefGoogle Scholar
  42. 42.
    Harper DM (2009) Preliminary HPV vaccine results for women older than 25 years. Lancet 373:1921–1922PubMedCrossRefGoogle Scholar
  43. 43.
    Harper DM, Franco EL, Wheeler C et al (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757–1765PubMedCrossRefGoogle Scholar
  44. 44.
    Harper DM, Franco EL, Wheeler CM et al (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247–1255PubMedCrossRefGoogle Scholar
  45. 45.
    Hepburn HM, Kaufmann AM (2009) Nobel price for vaccination against cervical cancer: current data and guidelines. Internist (Berl) 50:617–626Google Scholar
  46. 46.
    Hildesheim A, Herrero R, Wacholder S et al (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743–753PubMedCrossRefGoogle Scholar
  47. 47.
    Hobbs CG, Sterne JA, Bailey M et al (2006) Human papillomavirus and head and neck cancer: a systematic review and meta-analysis. Clin Otolaryngol 31:259–266PubMedCrossRefGoogle Scholar
  48. 48.
    Hoffmann TK, Arsov C, Schirlau K et al (2006) T cells specific for HPV 16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 118:1984–1991PubMedCrossRefGoogle Scholar
  49. 49.
    Klussmann JP, Gultekin E, Weissenborn SJ et al (2003) Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 162:747–753PubMedGoogle Scholar
  50. 50.
    Klussmann JP, Preuss SF, Speel EJ (2009) Humane Papillomviren und Oropharynxkarzinome: Molekulare Interaktion und klinische Auswirkung. HNO 57:113–122PubMedCrossRefGoogle Scholar
  51. 51.
    Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102:3–8PubMedCrossRefGoogle Scholar
  52. 52.
    Koutsky LA, Ault KA, Wheeler CM et al; Proof of Principle Study Investigators (2002) A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 347:1645–1651Google Scholar
  53. 53.
    Kreimer AR, Alberg AJ, Daniel R et al (2004) Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 189:686–698PubMedCrossRefGoogle Scholar
  54. 54.
    Kreimer AR, Clifford GM, Boyle P et al (2005) Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 14:467–475PubMedCrossRefGoogle Scholar
  55. 55.
    Kuss I, Hathaway B, Ferris RL et al (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10:3755–3762PubMedCrossRefGoogle Scholar
  56. 56.
    Kuss I, Hathaway B, Ferris RL et al (2005) Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. Adv Otorhinolaryngol 62:161–172PubMedGoogle Scholar
  57. 57.
    Licitra L, Perrone F, Bossi P et al (2006) High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636PubMedCrossRefGoogle Scholar
  58. 58.
    Lindeberg H, Oster S, Oxlund I et al (1986) Laryngeal papillomas: classification and course. Clin Otolaryngol Allied Sci 11:423–429PubMedCrossRefGoogle Scholar
  59. 59.
    Manhart LE, Holmes KK, Koutsky LA et al (2006) Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy. Sex Transm Dis 33:502–508PubMedCrossRefGoogle Scholar
  60. 60.
    Mao C, Koutsky LA, Ault KA et al (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107:18-27PubMedGoogle Scholar
  61. 61.
    Mashberg A (1993) Head and neck cancer. N Engl J Med 328:1783; author reply 1784PubMedCrossRefGoogle Scholar
  62. 62.
    Molling JW, De Gruijl TD, Glim J et al (2007) CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer 121:1749–1755PubMedCrossRefGoogle Scholar
  63. 63.
    Mork J, Lie AK, Glattre E et al (2001) Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 344:1125–1131PubMedCrossRefGoogle Scholar
  64. 64.
    Moscicki AB, Shiboski S, Broering J et al (1998) The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132:277–284PubMedCrossRefGoogle Scholar
  65. 65.
    Munoz N, Bosch FX, De Sanjose S et al (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348:518–527PubMedCrossRefGoogle Scholar
  66. 66.
    Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170PubMedCrossRefGoogle Scholar
  67. 67.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  68. 68.
    Pathirana D, Hillemanns P, Petry KU et al (2009) Short version of the German evidence-based guidelines for prophylactic vaccination against HPV-associated neoplasia. Vaccine 27:4551–4559PubMedCrossRefGoogle Scholar
  69. 69.
    Pawlita M, Gissmann L (2009) Recurrent respiratory papillomatosis: indication for HPV vaccination? Dtsch Med Wochenschr 134(Suppl 2):S100–S102PubMedCrossRefGoogle Scholar
  70. 70.
    Pintos J, Franco EL, Black MJ et al (1999) Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 85:1903–1909PubMedGoogle Scholar
  71. 71.
    Reimers N, Kasper HU, Weissenborn SJ et al (2007) Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 120:1731–1738PubMedCrossRefGoogle Scholar
  72. 72.
    Richardson H, Kelsall G, Tellier P et al (2003) The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12:485–490PubMedGoogle Scholar
  73. 73.
    Rihkanen H, Aaltonen LM, Syrjanen SM (1993) Human papillomavirus in laryngeal papillomas and in adjacent normal epithelium. Clin Otolaryngol Allied Sci 18:470–474PubMedCrossRefGoogle Scholar
  74. 74.
    Ritchie JM, Smith EM, Summersgill KF et al (2003) Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 104:336–344PubMedCrossRefGoogle Scholar
  75. 75.
    Robert-Koch-Institut (2009) Impfung gegen HPV – Aktuelle Bewertung der STIKO. Epidemiologisches Bulletin 32/09. http://www.rki.de/cln_153/nn_1378492/DE/Content/Infekt/EpidBull/Archiv/2009/32__09,templateId=raw,property=publicationFile.pdf/32_09.pdf:319–328Google Scholar
  76. 76.
    Robert-Koch-Institut (2007) Impfung gegen humane Papillomaviren (HPV) für Mädchen und Frauen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiologisches Bulletin 12/07. http://www.rki.de/cln_153/nn_264978/DE/Content/Infekt/EpidBull/Archiv/2007/12__07.html?__nnn=true:97–103Google Scholar
  77. 77.
    Schaefer C, Kim GG, Albers A et al (2005) Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br J Cancer 92:913–920PubMedCrossRefGoogle Scholar
  78. 78.
    Schiffman M, Kjaer SK (2003) Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 14–19Google Scholar
  79. 79.
    Schlecht NF, Platt RW, Duarte-Franco E et al (2003) Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95:1336–1343PubMedGoogle Scholar
  80. 80.
    Schneider A, Koutsky LA (1992) Natural history and epidemiological features of genital HPV infection. IARC Sci Publ 25–52Google Scholar
  81. 81.
    Schwartz SM, Daling JR, Doody DR et al (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626–1636PubMedCrossRefGoogle Scholar
  82. 82.
    Schwarz TF (2008) AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines 7:1465–1473PubMedCrossRefGoogle Scholar
  83. 83.
    Siegrist CA, Lewis EM, Eskola J et al (2007) Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26:979–984PubMedCrossRefGoogle Scholar
  84. 84.
    Sillman FH, Sentovich S, Shaffer D (1997) Ano-genital neoplasia in renal transplant patients. Ann Transplant 2:59–66PubMedGoogle Scholar
  85. 85.
    Smith EM, Ritchie JM, Summersgill KF et al (2004) Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96:449–455PubMedCrossRefGoogle Scholar
  86. 86.
    Smith EM, Ritchie JM, Summersgill KF et al (2004) Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 108:766–772PubMedCrossRefGoogle Scholar
  87. 87.
    Smith EM, Summersgill KF, Allen J et al (2000) Human papillomavirus and risk of laryngeal cancer. Ann Otol Rhinol Laryngol 109:1069–1076PubMedGoogle Scholar
  88. 88.
    Stanley MA (2002) Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 27:571–577PubMedCrossRefGoogle Scholar
  89. 89.
    Strauss L, Bergmann C, Gooding W et al (2007) The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6301–6311PubMedCrossRefGoogle Scholar
  90. 90.
    Syrjanen S (2005) Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32(Suppl 1):S59–S66PubMedCrossRefGoogle Scholar
  91. 91.
    Tenti P, Zappatore R, Migliora P et al (1999) Perinatal transmission of human papillomavirus from gravidas with latent infections. Obstet Gynecol 93:475–479PubMedCrossRefGoogle Scholar
  92. 92.
    Valdespino V, Gorodezky C, Ortiz V et al (2005) HPV 16-specific cytotoxic T lymphocyte responses are detected in all HPV 16-positive cervical cancer patients. Gynecol Oncol 96:92–102PubMedCrossRefGoogle Scholar
  93. 93.
    Vambutas A, Devoti J, Pinn W et al (2001) Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 101:94–99PubMedCrossRefGoogle Scholar
  94. 94.
    Van Poelgeest MI, Nijhuis ER, Kwappenberg KM et al (2006) Distinct regulation and impact of type 1 T-cell immunity against HPV 16 L1, E2 and E6 antigens during HPV 16-induced cervical infection and neoplasia. Int J Cancer 118:675–683CrossRefGoogle Scholar
  95. 95.
    Villa LL, Ault KA, Giuliano AR et al (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16 and 18. Vaccine 24:5571–5583PubMedCrossRefGoogle Scholar
  96. 96.
    Villa LL, Costa RL, Petta CA et al (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271–278PubMedCrossRefGoogle Scholar
  97. 97.
    Vinokurova S, Wentzensen N, Einenkel J et al (2005) Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst 97:1816–1821PubMedCrossRefGoogle Scholar
  98. 98.
    Viscidi RP, Schiffman M, Hildesheim A et al (2004) Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13:324–327PubMedCrossRefGoogle Scholar
  99. 99.
    Vokes EE, Weichselbaum RR, Lippman SM et al (1993) Head and neck cancer. N Engl J Med 328:184–194PubMedCrossRefGoogle Scholar
  100. 100.
    Walboomers JM, Jacobs MV, Manos MM et al (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12–19PubMedCrossRefGoogle Scholar
  101. 101.
    Welters MJ, De Jong A, Van Den Eeden SJ et al (2003) Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res 63:636–641PubMedGoogle Scholar
  102. 102.
    Wiatrak BJ, Wiatrak DW, Broker TR et al (2004) Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114:1–23PubMedCrossRefGoogle Scholar
  103. 103.
    Zumbach K, Kisseljov F, Sacharova O et al (2000) Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int J Cancer 85:313–318PubMedCrossRefGoogle Scholar
  104. 104.
    Zur Hausen H (2001) Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 93:252–253CrossRefGoogle Scholar
  105. 105.
    Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342–350CrossRefGoogle Scholar
  106. 106.
    Adams M, Navabi H, Jasani B et al. (2003) Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 21:787-790PubMedCrossRefGoogle Scholar
  107. 107.
    Baldwin PJ, van der Burg SH, Boswell CM et al. (2003) Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res 9:5205-5213PubMedGoogle Scholar
  108. 108.
    Berry JM, Palefsky JM (2003) A review of human papillomavirus vaccines: from basic science to clinical trials. Front Biosci 8:s333-345PubMedCrossRefGoogle Scholar
  109. 109.
    Borysiewicz LK, Fiander A, Nimako M et al. (1996) A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 347:1523-1527PubMedCrossRefGoogle Scholar
  110. 110.
    Corona Gutierrez CM, Tinoco A, Lopez Contreras M et al. (2002) Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus. Hum Gene Ther 13:1127-1140CrossRefGoogle Scholar
  111. 111.
    Corona Gutierrez CM, Tinoco A, Navarro T et al. (2004) Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum Gene Ther 15:421-431CrossRefGoogle Scholar
  112. 112.
    Davidson EJ, Boswell CM, Sehr P et al. (2003) Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res 63:6032-6041PubMedGoogle Scholar
  113. 113.
    Davidson EJ, Faulkner RL, Sehr P et al. (2004) Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22:2722-2729PubMedCrossRefGoogle Scholar
  114. 114.
    De Jong A, O’Neill T, Khan AY et al. (2002) Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine 20:3456-3464CrossRefGoogle Scholar
  115. 115.
    Einstein MH, Kadish AS, Burk RD et al. (2007) Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 106:453-460PubMedCrossRefGoogle Scholar
  116. 116.
    Ferrara A, Nonn M, Sehr P et al. (2003) Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol 129:521-530PubMedCrossRefGoogle Scholar
  117. 117.
    Fiander AN, Tristram AJ, Davidson EJ et al. (2006) Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. Int J Gynecol Cancer 16:1075-1081PubMedCrossRefGoogle Scholar
  118. 118.
    Frazer IH, Quinn M, Nicklin JL et al. (2004) Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23:172-181PubMedCrossRefGoogle Scholar
  119. 119.
    Frazer IH, Thomas R, Zhou J et al. (1999) Potential strategies utilised by papillomavirus to evade host immunity. Immunol Rev 168:131-142PubMedCrossRefGoogle Scholar
  120. 120.
    Garcia F, Petry KU, Muderspach L et al. (2004) ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 103:317-326PubMedGoogle Scholar
  121. 121.
    Goldstone SE, Palefsky JM, Winnett MT et al. (2002) Activity of HspE7, a novel immunotherapy, in patients with anogenital warts. Dis Colon Rectum 45:502-507PubMedCrossRefGoogle Scholar
  122. 122.
    Hallez S, Simon P, Maudoux F et al. (2004) Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother 53:642-650PubMedCrossRefGoogle Scholar
  123. 123.
    Harper DM, Franco EL, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364:1757-1765PubMedCrossRefGoogle Scholar
  124. 124.
    Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255PubMedCrossRefGoogle Scholar
  125. 125.
    Kaufmann AM, Nieland JD, Jochmus I et al. (2007) Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121:2794-2800PubMedCrossRefGoogle Scholar
  126. 126.
    Kaufmann AM, Stern PL, Rankin EM et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin Cancer Res 8:3676-3685PubMedGoogle Scholar
  127. 127.
    Kawana K, Yasugi T, Kanda T et al. (2003) Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine 21:4256-4260PubMedCrossRefGoogle Scholar
  128. 128.
    Kenter GG, Welters MJ, Valentijn AR et al. (2008) Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 14:169-177PubMedCrossRefGoogle Scholar
  129. 129.
    Klencke B, Matijevic M, Urban RG et al. (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8:1028-1037PubMedGoogle Scholar
  130. 130.
    Lacey CJ, Thompson HS, Monteiro EF et al. (1999) Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. J Infect Dis 179:612-618PubMedCrossRefGoogle Scholar
  131. 131.
    Mao C, Koutsky LA, Ault KA et al. (2006) Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107:18-27PubMedGoogle Scholar
  132. 132.
    Muderspach L, Wilczynski S, Roman L et al. (2000) A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 6:3406-3416PubMedGoogle Scholar
  133. 133.
    Palefsky JM, Berry JM, Jay N et al. (2006) A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 20:1151-1155PubMedCrossRefGoogle Scholar
  134. 134.
    Ressing ME, Van Driel WJ, Brandt RM et al. (2000) Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. J Immunother 23:255-266PubMedCrossRefGoogle Scholar
  135. 135.
    Roman LD, Wilczynski S, Muderspach LI et al. (2007) A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. Gynecol Oncol 106:558-566PubMedCrossRefGoogle Scholar
  136. 136.
    Santin AD, Bellone S, Gokden M et al. (2002) Vaccination with HPV-18 E7-pulsed dendritic cells in a patient with metastatic cervical cancer. N Engl J Med 346:1752-1753PubMedCrossRefGoogle Scholar
  137. 137.
    Santin AD, Bellone S, Palmieri M et al. (2008) Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 82:1968-1979PubMedCrossRefGoogle Scholar
  138. 138.
    Sheets EE, Urban RG, Crum CP et al. (2003) Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am J Obstet Gynecol 188:916-926PubMedCrossRefGoogle Scholar
  139. 139.
    Smyth LJ, Van Poelgeest MI, Davidson EJ et al. (2004) Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res 10:2954-2961PubMedCrossRefGoogle Scholar
  140. 140.
    Steller MA, Gurski KJ, Murakami M et al. (1998) Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res 4:2103-2109PubMedGoogle Scholar
  141. 141.
    Thompson HS, Davies ML, Holding FP et al. (1999) Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 17:40-49PubMedCrossRefGoogle Scholar
  142. 142.
    Van Driel WJ, Kenter GG, Fleuren GJ et al. (1999) Immunotherapeutic strategies for cervical squamous carcinoma. Hematol Oncol Clin North Am 13:259-273CrossRefGoogle Scholar
  143. 143.
    Vandepapeliere P, Barrasso R, Meijer CJ et al. (2005) Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192:2099-2107PubMedCrossRefGoogle Scholar
  144. 144.
    Villa LL, Costa RL, Petta CA et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • A.E. Albers
    • 1
  • T.K. Hoffmann
    • 2
  • J.P. Klussmann
    • 3
  • A.M. Kaufmann
    • 4
  1. 1.Hals-Nasen-Ohren-KlinikCharité - Universitätsmedizin Berlin, Campus Benjamin FranklinBerlinDeutschland
  2. 2.Hals-Nasen-Ohren-KlinikUniversität EssenEssenDeutschland
  3. 3.Klinik für HNO-Heilkunde, Kopf-/Halschirurgie, Plastische OperationenUniversitätsklinikum Gießen und Marburg GmbHStandort GießenDeutschland
  4. 4.Gynäkologische Tumorimmunologie, Gynäkologie, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin und Campus MitteBerlinDeutschland

Personalised recommendations